Malaria rapid diagnostic tests (RDTs) are widely utilized by malaria control programs as part of case management because of their ease of use. Malaria RDTs are lateral-flow immunochromatographic devices that detect specific *Plasmodium* parasite antigens in blood samples[@b1]. At least three target antigens are captured by various commercially available malaria RDTs: histidine-rich protein 2 (HRP2), lactate dehydrogenase (LDH) and aldolase. Moreover, while most of the LDH and aldolase-based tests are pan-specific, the HRP2-based RDTs are specific for the unique *Plasmodium falciparum* protein (PfHRP2)[@b1].

*The pfhrp2 gene* (PlasmoDB gene ID: PF3D7_0831800) is 1063 bp and located subtelomerically on chromosome 8[@b2][@b3][@b4]. The gene is immediately flanked upstream by a *Plasmodium* exported protein of unknown function (pseudogene), PF3D7_0831900, and downstream by a putative heat shock protein 70 gene, PF3D7_0831700 ([Figure 1](#f1){ref-type="fig"}). Although the deletion of *pfhrp2* in laboratory-adapted *P. falciparum* strains has previously been documented, this phenomenon had not been observed in natural *P. falciparum* populations until 2010 when *P. falciparum* isolates collected from the Peruvian Amazon were shown to be *pfhrp2*-negative[@b5][@b6][@b7]. Even more recently, *pfhrp2*-negative parasite isolates have been detected in Brazil, Mali, Senegal and India[@b8][@b9][@b10][@b11]. The prevalence of this phenotype suggested that the *pfhrp2*-negative parasites were viable *in vivo* and capable of causing malaria. Extensive characterization of four *pfhrp2*-negative *P. falciparum* clinical isolates from Peru by whole genome microarray analysis revealed an approximately 20 kb deletion of the genome showing that the deletion is not restricted to *pfhrp2* itself but extends to a number of neighboring genes[@b12].

The *P. falciparum* parasite population structure in the Peruvian Amazon has previously been characterized as clonal[@b13][@b14]. Neutral microsatellite profiles of clinical samples collected between 1998 and 2001 revealed that the *P. falciparum* parasites in Peru consisted of at least five distinct clonal lineages. These clonal lineages, designated as A, B, C, D and E, each displayed a distinct drug resistance and neutral microsatellite-based genetic profile[@b14].

The objective of our study was to characterize the origin and possible reasons for the observed temporal and geographical expansion of *pfhrp2*-negative *P. falciparum* parasites in the Peruvian Amazon, where the highest levels of deletions have been documented[@b7]. We hypothesized that evidence of hitchhiking would be revealed once we analyzed the molecular signatures around Peruvian *pfhrp2* deletions if it evolved from a rare genetic event(s) and spread rapidly under selective pressure. To test our hypothesis, we utilized PCR-based amplification methods and microsatellite analysis to detect deletion of *pfhrp2* and its flanking genes in historical samples (malaria re-emergence peaked in the late 1990s in Peru), then ascertained whether the deletion genotype was restricted to certain clonal lineages. We then examined the pattern of deletion around the *pfhrp2* gene.

Results
=======

Comparison of population structure in parasites collected in 1998--2001 and 2003--2005
--------------------------------------------------------------------------------------

A total of 188 samples collected in Peru between 1998 and 2005 were used in this study ([Table 1](#t1){ref-type="table"}). Previous neutral microsatellite marker analysis of a set of *P. falciparum* samples collected in Peru during peak malaria expansion in the post-malaria eradication era (1998--2000) indicated a clonal population structure consisting of five clonal lineages (A, B, C, D and E)[@b14]. In the current study, we utilized the same seven neutral microsatellite markers ([Table 2](#t2){ref-type="table"}) to analyze samples collected between 1998 and 2001 and found that our results mirrored the previous finding of five clonal lineages as illustrated in [Figure 2a](#f2){ref-type="fig"}.

Similar neutral microsatellite analysis performed on samples collected in 2003--2005 predicted the presence of at least eight different population clusters ([Figure 2b](#f2){ref-type="fig"}). Only the D lineage persisted after 1998--2001 to form one of the eight clusters; all other lineages (A, B, C and E) were undetectable in the samples collected in 2003--2005. In addition to lineage D, seven new clusters emerged: A/B; A/C; B/C; C/D; C/D/E; X and Z ([Figure 2b](#f2){ref-type="fig"}). Analysis of the data from neutral microsatellite analysis, combined with the Structure program output predicting the membership of certain samples into more than one cluster ([Figure 2b](#f2){ref-type="fig"}), revealed that five of the seven newly emerged clusters (A/B, A/C, B/C, C/D and C/D/E) were hybrids resulting from outcrossing of the five lineages A, B, C, D and E that were present in 1998--2001. The samples in each new hybrid cluster shared neutral microsatellite allele sizes found in the original five lineages A to E (Data not shown). Clusters X and Z consisted of isolates that had some neutral microsatellite locus sizes that had been seen in the 1998--2001 samples while other locus sizes were new.

The genetic relationship among the parasite isolates was further analyzed using the median joining network method in which neutral microsatellite markers were employed ([Figure 3](#f3){ref-type="fig"}). Network analysis allowed for closer analysis of the genetic relationships among the clusters predicted by the Structure program. As observed in a previous study[@b14], samples collected in 1998--2001 had limited diversity within each of the five clonal lineages ([Figure 3a](#f3){ref-type="fig"}). In contrast, greater genetic diversity was evident among the 2003--2005 isolates from the Network analysis; individual parasites were no longer grouped strictly by their Structure-assigned clusters ([Figure 3b](#f3){ref-type="fig"}). Newly emerged A/C and B/C clusters formed independent single major groups (except two isolates in B/C that showed minor variations) indicating high levels of genetic similarity within each of these clusters. Although the C/D/E cluster formed a major group within the network, the cluster also showed some genetic diversity, with seven isolates forming groups outside of the major group ([Figure 3b](#f3){ref-type="fig"}). The other four clusters (C/D, A/B, X and Z) were more randomly distributed, indicating high levels of genetic variation among each of these clusters, most likely due to outcrossing. It was evident that three members of the Z lineage clustered together with one set of A/B lineage isolates due to similarities in their neutral microsatellite allele sizes ([Figure 3b](#f3){ref-type="fig"}).

Prevalence of *pfhrp2*-deleted parasites in samples collected between 1998 and 2005
-----------------------------------------------------------------------------------

Our analysis revealed that *pfhrp2* was deleted in parasite isolates belonging to clonal lineages A, B, C and D in 1998--2001, with the highest prevalence of deletion found among samples from the D lineage (60%) followed by B (22.2%) and C (20.8%) lineages. *Pfhrp2*-negative parasites were less common in the A lineage (4.3%) ([Figure 4](#f4){ref-type="fig"}). Furthermore, the prevalence of *pfhrp2* deletion was around 20% in 1998--2001 and increased significantly to 40% by 2003--2005 (p = 0.0015; [Table 3](#t3){ref-type="table"}). Genetic deletions were not restricted to the *pfhrp2* gene alone, but were found to extend to neighboring genes. A greater proportion of parasites were found to have deleted PF3D7_0831900 (the gene located 5′ of *pfhrp2*) than those that had deleted the 3′ flanking gene, PF3D7_0831700 ([Table 3](#t3){ref-type="table"}).

Parasite haplotype structure in relation to the *pfhrp2* deletion phenotype
---------------------------------------------------------------------------

We had shown previously that each clonal lineage present in 1998--2001 (A to E) possessed a unique drug resistance haplotype[@b14]. In the current study, the regions flanking *pfhrp2* were genotyped using seven microsatellite markers located on chromosome 8 in order to understand the haplotype structure. Five of the seven *pfhrp2* microsatellite loci (−41, 1.4, 2.5, 5.2 and 15) were used to identify five unique *pfhrp2* haplotypes because these markers were detectable in most of the isolates genotyped in this study ([Table 2](#t2){ref-type="table"}). Two *pfhrp2* microsatellite loci (−9.5 and −3.8) were not used to define the *pfhrp2* haplotypes because they had been deleted in a number of *pfhrp2*-negative parasite isolates. These five *pfhrp2* haplotypes, α, β, γ, δ and ε, corresponded with the five clonal lineages of parasites (A to E) previously described ([Figure 5a](#f5){ref-type="fig"}; [Table 2](#t2){ref-type="table"}).

To investigate the evolving pattern of *pfhrp2* deletion in the Peruvian Amazon over time, the deletion patterns were determined for parasite isolates belonging to the five clonal lineages observed in 1998--2001 and the eight lineages seen in 2003--2005. There was clear evidence for *pfhrp2* deletion in all of the observed clonal lineages except E ([Figure 4](#f4){ref-type="fig"}). The distribution of *pfhrp2* deletions among the *pfhrp2* haplotypes is illustrated in the Network diagrams of [Figure 5](#f5){ref-type="fig"}. In 1998--2001, the highest proportion of *pfhrp2* deletion was found in the δ haplotype (9/15; 60%) followed by β (4/18; 22.2%), γ (5/25 20%) and α (1/23; 4.3%) ([Figure 5a](#f5){ref-type="fig"}). Deletion was not observed in the ε haplotype ([Figure 5a](#f5){ref-type="fig"}).

Even though four of the five clonal lineages (A, B, C, and E) could not be detected by 2003--2005, all five *pfhrp2* haplotypes (α, β, γ, δ and ε) that were present in 1998--2001 persisted in the 2003--2005 set of samples ([Figure 5](#f5){ref-type="fig"}). We also observed four isolates from the 2003--2005 sample set with *pfhrp2* microsatellite alleles that had not been detected in previous years. The allele sizes differed among these samples. We assigned them to a sixth haplotype, 'ψ\' ([Figure 5b](#f5){ref-type="fig"}). The highest level of deletion was found within the δ haplotype (23/26; 88.5%). This was followed by γ (4/16; 25%), β (7/40; 17.5%) and α (1/9; 11.1%). The one sample belonging to the ε haplotype was *pfhrp2*-positive, while all four ψ haplotype samples were *pfhrp2*-negative.

Discussion
==========

We utilized microsatellites to investigate the genetic origins of *pfhrp2* deletion in Peruvian *P. falciparum* samples. We have shown that *pfhrp2*-negative parasites in the Peruvian Amazon have multiple origins. Deletion of *pfhrp2* in at least four out of the five clonal lineages found in 1998--2001 (A to E) strongly suggests that *pfhrp2* deletion has evolved independently in multiple genetic backgrounds ([Figures 4](#f4){ref-type="fig"} and [5](#f5){ref-type="fig"}).

Malaria transmission was reduced to very low levels in Peru after the implementation of the malaria eradication program in the 1950s. The disease re-emerged in the 1990s with peak *P. falciparum* transmission occurring between 1998--2000[@b14]. Our earlier work showed that the population structure of *P. falciparum* in Peru was clonal in nature during the peak transmission years and at least five clonal lineages were found[@b14]. Given this background and our access to historical samples that were collected during this peak period and in subsequent years (until 2005), we were interested in determining the influence of increased transmission and clonal population structure on the evolution of *pfhrp2* gene deletions. In this study, we have found that each of these previously defined clonal populations has a distinct *pfhrp2* haplotype background based on five *pfhrp2* microsatellite loci: −41, 1.4, 2.5, 5.2 and 15 ([Table 2](#t2){ref-type="table"}). This distinction has allowed us to determine the genetic origins of *pfhrp2* deletion in these populations. However, since the historical samples available to us only went as far back as 1998, we could not further assess when these deletion events originated and spread. It is also unclear whether the deletion events originated in Peru and expanded recently due to some selective pressure.

We speculated previously, based on the drug resistance haplotype history, that clonal lineages C, D and E may have been descendants of *P. falciparum* populations from the Pacific Coast/Andean region of Colombia and Ecuador[@b14]. On the other hand, clonal lineages A and B were ancestrally related to parasites from the Amazon region of Brazil[@b14]. The occurrence of *pfhrp2* deletions in these two distinct ancestral lineages of parasites raises the question whether this deletion occurred before these parasites migrated to Peru or whether it was a more recent event. If these deletion events occurred before the introduction of the clonal populations to Peru, then one would expect to find *pfhrp2*-negative parasites in the Colombian coast/Andean region as well as in the Brazilian Amazon. Analysis of parasite samples from these regions will provide further insights into the evolutionary history of these deletions.

The observed increase in the proportion of *pfhrp2*-negative parasites from 20% in 1998--2001 to 40% in 2003--2005 ([Table 3](#t3){ref-type="table"}) has major implications for the implementation of PfHRP2-based RDTs in the Peruvian Amazon. In one study, a comparable increase in *pfhrp2*-negative parasites was observed while testing a limited number of samples collected in the Peruvian Amazon during a ten-year period from 1996 to 2006[@b7]. It is not clear whether any biological selection process may have favored the expansion of *pfhrp2* deleted parasites in this region and if it is still ongoing.

*Pfhrp2* deletion was restricted to the four clonal lineages A to D observed in 1998--2001, but was also observed in the hybrid clusters that emerged between 2003--2005 ([Figures 4](#f4){ref-type="fig"} and [5b](#f5){ref-type="fig"}). Our data ([Figure 3b](#f3){ref-type="fig"}) is consistent with previous studies suggesting the emergence of new clonal parasite lineages due to outcrossing among the ancestral lineages[@b13][@b14]. Although seven entirely new hybrid clusters emerged between 2003 and 2005 (clonal lineages A, B, C and E were not detected), most of these parasites had each inherited one of the five *pfhrp2* haplotypes (α to ε) found at the earlier time point. The continued inheritance of α to ε haplotypes among the newly emerged clusters suggest that these parasites are not necessarily due to new introductions but due to admixture of historical samples present in this region[@b13][@b14]. There was limited recombination among the *pfhrp2* haplotypes because only four of the ninety six isolates from 2003--2005 showed a different haplotype structure (ψ) while the rest retained their ancestral haplotype structure.

Although this study has clearly indicated multiple origins for *pfhrp2* deletion, it remains to be determined if there is selective pressure favoring the spread of *pfhrp2*-negative parasites. This question could not be adequately answered in this study due to limited numbers of genetic loci and geographical areas studied, and the use of historical samples from a relatively short time period (1998--2005). However, we can hypothesize various reasons for the spread of *pfhrp2*-deleted parasites. One possibility is that changes in drug treatment policies around this period (chloroquine and sulfadoxine-pyrimethamine (SP) were replaced with artemisinin combination therapy, ACT, in 2001) could have favored the expansion of these new hybrids. However, there was no clear evidence to support this hypothesis. It should be noted that only lineages A and B carried highly SP-resistant dihydrofolate reductase (*pfdhfr*; located on chromosome 4) and dihydropteroate synthase (*pfdhps*; located on chromosome 8) genotypes. We had previously observed a decline in the highly resistant *pfdhfr* and *pfdhps* lineages from 1998--2001 to 2006[@b15][@b16]. This decline may have impacted the evolution of these clonal lineages[@b14]. However, *pfhrp2* haplotype β from the B clonal lineage did not disappear within the same time period, suggesting that while drug policy changes may have impacted the fitness of the SP-resistant genotypes, they had no apparent effect on the *pfhrp2* locus on chromosome 8.

Continuous use of PfHRP2-based RDTs may also create a selective pressure favoring the expansion of *pfhrp2*-negative parasite lineages. However, RDTs were not routinely used for malaria case management in Peru because microscopic analysis was available in most health facilities. Therefore, it is unlikely that any limited use of PfHRP2-based RDTs by itself contributed to the selection of a *pfhrp2*-negative parasite population in Peru between 1998 and 2006. It is unclear whether bottlenecks and uneven distribution of limited *P. falciparum* clonal lineages, in addition to their underlying population structure, could account for the selection of *pfhrp2*-negative parasites in Peru. Since there is a wider deletion in the genomic region flanking *pfhrp2*, there is also the possibility that selection may be acting on a nearby target that is totally independent of *pfhrp2* and is yet to be discovered.

*Pfhrp2* deletions are significant because of the impact they have on the use of PfHRP2-based RDTs for malaria detection in South America. For this reason, the ability to monitor parasites that are *pfhrp2*-positive but are negative for the upstream flanking gene PF3D7_0831900 and surrounding microsatellite loci may allow one to predict where subsequent generations of *pfhrp2*-negative parasites could appear. The biological significance of the presence of *pfhrp2*-negative *P. falciparum* parasites in Peru is unclear. Given our findings regarding the genetic origins of *pfhrp2*-deleted *P. falciparum* parasites in the Peruvian Amazon, the next step would be to determine if any selective force is influencing the increase in parasites with this deletion. The nature, gene target and effect of this selective force on the *P. falciparum* parasite population will be of interest to those living in regions where *pfhrp2*-deletion has recently been reported, including Mali and India, albeit at much lower levels than that seen in Peru[@b9][@b11]. Further studies of parasite populations from other regions will provide clarity regarding this genotype.

In summary, our study provides evidence that the expansion of *pfhrp2*-negative *P. falciparum* parasites in Peru originated from multiple genetic backgrounds, rather than being caused by selection for a single, rare deletion event. Reports of low levels of *pfhrp2*-negative parasites in other geographically distant regions suggest that the *pfhrp2* deletion may continue to occur randomly on other genetic backgrounds. Further understanding of the biological features that may favor the selection and spread of parasites with genomic deletions in the *pfhrp2* region will be essential to determine the evolutionary basis for the spread of these parasites.

Methods
=======

Peru study sites and *P. falciparum* clinical isolates
------------------------------------------------------

The details of study sample collection year and location are provided in [Table 1](#t1){ref-type="table"}. The 92 *P. falciparum* parasite samples used in this study (collected from 1998--2001) were obtained using sample collection protocols that were approved by the Ethical Review Committees on the Instituto Nacional de Salud, U.S. Naval Medical Research Center Institutional Review Board, the Universidad Peruana Cayetano Heredia and the U.S. Centers for Disease Control and Prevention in compliance with all applicable federal regulations governing the protection of human subjects.

We retrospectively used 96 parasite isolates that were collected from 2003--2005 for use in studies investigating *pfhrp2* deletion. These studies were approved by the Ethical Review Committee of Universidad Peruana Cayetano Heredia, Peru. Permission to test these samples retrospectively at the CDC was also obtained. Written informed consent was provided by study participants and/or their legal guardians.

DNA isolation and genotyping of *pfhrp2* and flanking genes
-----------------------------------------------------------

DNA was isolated from filter paper blood spots or whole blood using the QIAamp DNA blood mini kit (QIAGEN, Valencia, CA) in accordance with the manufacturer\'s instructions. Confirmation of *P. falciparum* infection was conducted by PCR amplification of the *18S* ribosomal gene using methods described by Singh *et al*[@b17].

Samples that were positive for *P. falciparum* were then tested for *pfhrp2*. Two sets of primers were designed to amplify a 228 bp fragment of *pfhrp2* using a nested PCR protocol. The outward forward primer was 5′-GGTTTCCTTCTCAAAAAATAAAG-3′ and outward reverse primer was 5′-TCTACATGTGCTTGAGTTTCG-3′. The secondary reaction utilized 5′-GTATTATCCGCTGCCGTTTTTGCC-3′ (forward) and 5′-CTACACAAGTTATTATTAAATGCGGAA-3′ (reverse) primers. The cycling conditions were 95°C/5 min; 30 cycles of 95°C/30 sec, 55°C/30 sec, 68°C/30 sec; 68°C/5 min (primary reaction) and 95°C/5 min; 30 cycles of 95°C/30 sec, 62°C/30 sec, 68°C/30 sec; 68°C/5 min (secondary reaction). *18s rRNA*-positive samples were identified as *pfhrp2*-negative if there was a failure to amplify the latter gene after two attempts.

Flanking genes *pfhrp2 -* PF3D7_0831900 (5.535 kb upstream) and PF3D7_0831700 (6.4 kb downstream) ([Figure 1](#f1){ref-type="fig"})-- were amplified utilizing the following primers: For PF3D7_0831900, the outward forward primer was 5′- GAT ATC ATT AGA AAA CAA GAG CTT AG -3′ and outward reverse primer was 5′- TAT CCA ATC CTT CCT TTG CAA CAC C -3′. The secondary reaction utilized 5′- TAT GAA CGC AAT TTA AGT GAG GCA G -3′ (forward) and 5′- TAT CCA ATC CTT CCT TTG CAA CAC C -3′ (reverse) primers. For PF3D7_0831700, the outward forward primer was 5′- AGA CAA GCT ACC AAA GAT GCA GGT G -3′ and outward reverse primer was 5′- TAA ATG TGT ATC TCC TGA GGT AGC -3′. The secondary reaction utilized 5′- CCA TTG CTG GTT TAA ATG TTT TAA G -3′ (forward) and 5′- TAA ATG TGT ATC TCC TGA GGT AGC -3′ (reverse) primers. For all samples, the reaction conditions were as follows: 95°C/5 min; 30 cycles of 95°C/30 sec, **X**°C/30 sec, 68°C/30 sec; 68°C/5 min, where X, the annealing temperature, was between 55--62°C depending on the primer pair used.

Multilocus genotyping
---------------------

Whole genome amplified DNA (REPLI-g Whole Genome Amplification kit, Qiagen, Valencia, CA) samples were assayed for seven putatively neutral microsatellites and seven microsatellites flanking *pfhrp2*. The neutral loci have previously been described and used in various studies in South America[@b18][@b19][@b20][@b21][@b22]. TA1 located on chromosome 6; poly α, chromosome 4; PfPK2, chromosome 12; TA109, chromosome 6; and 2490, chromosome 10. The last two neutral microsatellite loci used were C2M34 (chromosome 2) and C3M69 (chromosome 3)[@b23]. Additionally, we utilized seven microsatellites flanking *pfhrp2* at the following positions: −41 kb, −9.5 kb, −3.8 kb, 1.4 kb, 2.5 kb, 5.2 kb and 15 kb ([Figure 1](#f1){ref-type="fig"}). Upstream distances (negative values) were calculated from the start codon of *pfhrp2* and downstream distances (positive values) calculated from the gene\'s stop codon. If a sample failed to amplify any of the fourteen microsatellite loci, the PCR was repeated. If there was no amplification after two attempts, it was recorded that the particular locus had been deleted.

The amplification products were labeled with fluorescent dyes (HEX or FAM) and assayed for size on an Applied Biosystems 3130×l sequencer. The fragments were then scored with GeneMapper software v.3.7 (Applied Biosystems, Foster City, CA) using default microsatellite settings, whereby bands smaller than 500 relative fluorescence units (rfu) were defined as background. Samples for which we obtained no amplification in some loci were re-analyzed to complete the haplotypes.

Cluster analysis
----------------

In order to examine the population structure of *P. falciparum* isolates collected in Peru between 1998--2001 and 2003--2005, we used a Bayesian approach to infer the number of genetically related clusters (*K*) from the individual microsatellite haplotype profiles generated using seven neutral microsatellites. Neutral microsatellite analysis was implemented with Structure v2.3.3[@b24]. Any locus that we failed to amplify was assigned a null value (−9) as recommended by Structure. Although we had prior information on the presence of five clonal lineages in this population between 1998 and 2001[@b13][@b14], we predicted that there would be a change in the number of resulting clusters due to recombination among the clonal lineages. Therefore, we chose to test the likelihood of finding between one and ten clusters in this population (*K* = 1 to *K* = 10). We performed twenty replicates of the clustering algorithm for each value of *K* with a burn-in period of 10,000 iterations and 100,000 Markov Chain Monte Carlo replications. We used the admixture model with correlated allele frequencies[@b25]. The most likely number of clusters was defined by calculating the Δ*K* value as described by Evanno *et al*[@b26]. The Evanno method was implemented by inputting our data from Structure into the Structure Harvester program (<http://taylor0.biology.ucla.edu/struct_harvest/>).

Network analysis
----------------

To determine the relatedness of the samples collected in 1998--2001 and 2003--2005, we created median-joining network diagrams using Network v. 4.6.1.0 (fluxus-engineering.com)[@b27] and neutral microsatellite data from the seven neutral microsatellites. Any locus that we failed to amplify was assigned a null value (99) for the purposes of analysis.

Statistical analysis
--------------------

The proportion of *pfhrp2*-negative parasites collected in 1998--2001 and in 2003--2005 were compared using the chi-square test. An α of 0.05 was our threshold of statistical significance.
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![Location of *pfhrp2* and its flanking genes.\
*Pfhrp2* is located subtelomerically (position 1,374,236 to 1,375,299) on chromosome 8. The seven microsatellites flanking *pfhrp2* are shown in boxes; each value indicates the distance (in kilobases) of a microsatellite locus either upstream (negative values) or downstream (positive values) of the start and stop codons of *pfhrp2,* respectively. The two genes flanking *pfhrp2* are shown and their old gene IDs (Mal7p1.xxx) are included below the current PlasmoDB designations. Gene location and information were obtained from PlasmoDB v.9.1 (<http://plasmodb.org/plasmo/>).](srep02797-f1){#f1}

![Bayesian cluster analysis of Iquitos samples.\
The predicted number of likely clusters (*K*) for (a) samples collected in 1998--2001 (N = 92) was *K* = 5 while for (b) samples collected in 2003--2005 (N = 96) was *K* = 8. Each color corresponds to a population classified by Structure v 2.3.3 and each individual isolate is represented by a vertical bar. The Y axis represents the estimated proportion of membership of an individual to each predicted population cluster.](srep02797-f2){#f2}

![Median joining network analysis of *P. falciparum* samples collected in Iquitos in (a) 1998--2001 and (b) 2003--2005.\
The genetic relationships among parasites were constructed using the seven neutral microsatellite loci shown on [Table 2](#t2){ref-type="table"}. The distinct lineages are rendered in different colors and circle sizes are proportional to the number of samples assigned to a particular lineage. The number of samples assigned to each lineage by Structure analysis are shown in parentheses.](srep02797-f3){#f3}

![Prevalence of *pfhrp2* among the clonal lineages identified in Iquitos.\
Clinical samples were collected in 1998--2001 (N = 92) and 2003--2005 (N = 96). Dark grey boxes represent the proportion of *pfhrp2*-positive samples while light grey boxes represent *pfhrp2*-negative isolates. The clonal lineage assignments are indicated along the x-axis.](srep02797-f4){#f4}

![Prevalence of *pfhrp2* deletion among the *P. falciparum* haplotypes found in Peru.\
The genetic relationships among parasite isolates collected in (a) 1998--2001 and (b) 2003--2005 were constructed using the seven neutral microsatellite loci shown on [Table 2](#t2){ref-type="table"}. Blue color represents the proportion of *pfhrp2*-positive samples while yellow indicates the proportion of *pfhrp2*-negative samples. Additionally, the *pfhrp2* microsatellite-based haplotypes are labeled and highlighted. (b) Circle circumferences are proportional to the number of samples that belonged to a particular haplotype.](srep02797-f5){#f5}

###### Origin of *P. falciparum* samples collected from Peru

  Study area (Department)                        Collection years   Number of samples     Data set
  --------------------------------------------- ------------------ ------------------- ---------------
  Padre cocha (Loreto), Caballococha (Loreto)       1998--2000             82           '1998--2001\'
  Bellavista (Piura)                                   2001                10           '1998--2001\'
  Iquitos (Loreto)                                  2003--2005             96           '2003--2005\'

###### Baseline (1998--2001) Neutral and *Pfhrp2* flanking microsatellite marker profiles for Peru samples. The table shows the microsatellite loci sizes obtained for each of the five clonal lineages from samples collected in 1998--2001. TA1, Polyα, PfPk2, TA109, 2490, C2M34 and C3M69 are neutral microsatellite loci[@b18][@b19][@b20][@b21][@b22][@b23]. −41, −9.5, −3.8 are microsatellite loci located upstream of *pfhrp2* while 1.4, 2.5, 5.2 and 15 are loci located downstream of *pfhrp2* on chromosome 8. *Pfhrp2* haplotypes were determined based on the five *pfhrp2* flanking loci −41, 1.4, 2.5, 5.2 and 15, which were amplified in both *pfhrp2*-positive and *pfhrp2*-negative isolates. The loci −9.5, and −3.8 were deleted in many *pfhrp2*-negative samples

  Chromosome             6      4      12       6      10      2       3                                 8                                           
  -------------------- ----- ------- ------- ------- ------ ------- ------- ------------------------ ---------- ------ ------ ----- ----- ---------- -----
  **Locus**             TA1   Polyα   PfPk2   TA109   2490   C2M34   C3M69                              −41      −9.5   −3.8   1.4   2.5     5.2      15
  **Clonal lineage**                                                         ***Pfhrp2* haplotype**                                                     
  **A**                 169    183     166     164     84     239     134              α              120, 124   182    141    231   142     171      168
  **B**                 172    183     172     164     84     226     149              β                120      173    139    246   155     180      172
  **C**                 178    164     163     160     80     246     136              γ                120      173    139    256   161   196, 201   177
  **D**                 172    161     175     160     80     233     122              δ                124      180    143    246   151     170      176
  **E**                 172    148     175     161     75     225     138              ε                119      172    153    240   161     217      162

###### Proportion of *pfhrp2* and flanking gene deletions in samples from different sites of the Peruvian Amazon. Data show the number (and percentage) of parasites with gene deletions out of total samples tested

                                Genes                                              
  ------------------------ --------------- --------------------------------------- ---------------
  Caballococha                  22/36                     **13/36**                     10/36
  Padre cocha                   14/46                     **6/46**                      3/46
  Bellavista                    0/10                      **0/10**                      0/10
  **Total (1998--2001)**    36/92 (39.1%)             **19/92 (20.7%)**             13/92 (14.1%)
  Iquitos                       43/96                     **39/96**                     11/96
  **Total (2003--2005)**        44.8%       **40.6%**[\*](#t3-fn1){ref-type="fn"}       11.5%

\*The increase in the proportion of *pfhrp2*-negative parasites from 1998--2001 to 2003--2005 was determined to be statistically significant (p = 0.0015) using the chi-square test.
